Sciema   Report issue

For profit Phase 4
Founded: Mainz Germany (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2019
NCT04030091
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Sciema UG

Active Ingredients

Drugs in Phase 4 Trials (1)

insulin human (humulin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1